QFITLIA (fitusiran)
TherapySanofi
QFITLIA (fitusiran) by Sanofi is an RNA-based therapy designed for prophylactic use in hemophilia A or B.
Approvals
1
Indications
1
Biomarkers
1
Mapped tests
1
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and QFITLIA. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where QFITLIA is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Hemophilia A patients with or without factor VIII inhibitors and Hemophilia B patients with or without IX inhibitors Non-cancer · Blood | Antithrombin III
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for QFITLIA.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering QFITLIA for eligible patients.
Test
INNOVANCE Antithrombin
Siemens Healthcare Diagnostic Products GmbH
Method
CHROMOGENIC_ASSAY
Specimen
Plasma
1 approvalView test profile →